Expert Interview
A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Ticker(s): BBIO, PFE, ALNYInstitution: Washington University St. Louis
- Director of the Cardio-Oncology Center of Excellence and Co-Director of the Amyloid Center of Excellence at the Washington University St. Louis.
- Treats ~ 10 ATTR-CM patients monthly.
- Clinical and Research interests include better characterizing and understanding cardiovascular disease associated with cancer treatment, and diagnosis and managment of cardiac amyloidosis
why do you think Part A of ATTRibute failed?
Added By: wilson_adminWhat do you think of the Part B probability of success?
Added By: wilson_adminHow do you view acoramidis compared to other options
Added By: wilson_adminThinking of the three entrants into the CM arena - vutrisiran, eplontersen, and acoramidis, characterize what you believe are the differentiating advantages/disadvantages of each?
Added By: userad5df6c5Describe how you see the marketing shaking out with the emergence of three different players with three different solutions (vutrisiran, eplontersen, and acoramidis) in the aTTR-CM market? Are there unique patient types for each?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
